A novel cell-penetrating peptide discovered via phage display improved mRNA lipid nanoparticle delivery to cystic fibrosis lung cells by up to 7.8-fold in vitro and 3.4-fold in mouse lungs.
7.8× delivery boostPeptide-decorated lipid nanoparticles delivered mRNA nearly 8 times more effectively to primary CF bronchial cells than unmodified nanoparticles, with 3.4-fold improvement confirmed in mouse lungs
What the researchers found
A lead peptide identified from phage display against primary CF bronchial epithelial cells enhanced mRNA lipid nanoparticle delivery by 7.8-fold in vitro (primary human CF bronchial epithelia) and 3.4-fold in vivo (mouse lungs). The peptide facilitated specific uptake into lung epithelial cells relative to other cell types.
Why it matters
Gene therapy could potentially cure cystic fibrosis by delivering correct copies of the CFTR gene, but getting the therapeutic cargo past airway mucus and into the right cells has been the main technical barrier. This peptide-guided approach represents a significant step toward making lung-targeted gene therapy for CF a reality.
The numbers in context
Screening was performed against primary human bronchial epithelial cells from CF patients cultured at air-liquid interface for realistic conditions.
How the study worked
Phage display screening against primary human bronchial epithelial cells from CF patients cultured at air-liquid interface (producing mucus). Lead peptide incorporated into lipid nanoparticles carrying reporter mRNA (luciferase). Delivery efficiency measured in vitro on primary CF cells and in vivo in mouse lungs.
Who was studied
Primary human cystic fibrosis bronchial epithelial cells
What this study cannot tell us
Mouse lungs differ significantly from human CF lungs in mucus composition and thickness. The fold-improvements, while significant, may need to be larger for therapeutic efficacy. Long-term safety of repeated peptide-nanoparticle administration to the lungs is unknown. The study used reporter mRNA, not therapeutic CFTR mRNA.
How to read the evidence
Preliminary evidence from a well-designed preclinical study using clinically relevant cell models (patient-derived CF cells at air-liquid interface) and in vivo mouse validation.
When this study was published
Published in 2024, representing cutting-edge research at the intersection of peptide science and gene therapy delivery.
The bigger picture
Cystic fibrosis is caused by a single gene defect, making it an ideal candidate for gene therapy. While mRNA and gene editing technologies have advanced rapidly, delivery to the lungs remains the biggest challenge. This peptide-targeting approach could be applicable not just to CF but to other lung diseases where targeted delivery through mucus barriers is needed.
Questions still open
- Will the peptide-nanoparticle system deliver functional CFTR mRNA at levels sufficient to restore chloride channel function in CF airways?
- Does the peptide maintain its mucus-penetrating ability in severely affected CF lungs with much thicker mucus?
Common questions
What is phage display and how does it find useful peptides?
Could this approach cure cystic fibrosis?
Read the original research
Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.
Molecular therapy. Nucleic acids, 35(4), 102375
Citation
Soto, Melissa R; Lewis, Mae M; Leal, Jasmim; Pan, Yuting; Mohanty, Rashmi P; Veyssi, Arian; Maier, Esther Y; Heiser, Brittany J; Ghosh, Debadyuti. (2024). Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lung epithelia.. Molecular therapy. Nucleic acids, 35(4), 102375. https://doi.org/10.1016/j.omtn.2024.102375